MaxQ News

MaxQ AI Continues to Deploy Intelligence-Based Clinical Decision Support Technology Across the Healthcare Industry

FDA Clearance for Accipio Ix™ Intracranial Hemorrhage Platform

Agreement will pave the way for integration of MaxQ AI’s artificial intelligence Accipio Ix™ intracranial hemorrhage software into NeuroLogica’s medical imaging platforms in the U.S. and E.U. acute care market

Tel Aviv, Israel and Andover, MA – November 7, 2018 – MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers and physicians in acute care settings to have access to this artificial intelligence (AI) software designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of intracranial hemorrhage (ICH), commonly known as a brain bleed.

Samsung NeuroLogica and MedyMatch Technology Announce Strategic Alliance to Bring “A.I. to the Curbside”

IBM AND MAXQ AI FORM A NEW GO-TO-MARKET 

• IBM Watson Health Imaging signs multiyear OEM agreement to license MaxQ AI’s patient specific - point of care – cognitive decision support algorithms.
• The first application to be made available is MaxQ AI’s A.I. based intracranial hemorrhage detection.
• Go-To-Market will focus on the delivery of cognitive based clinical decision support tools to service the acute care marketplace through IBM Watson Health Imaging.

Tel Aviv, Israel – January 24, 2017 – IBM (NYSE: IBM) and MaxQ AI announced today a multi-year, go to market relationship to deliver MaxQ AI’s cognitive-based clinical decision support algorithms to the acute care marketplace. The initial application, to be distributed through IBM Watson Health Imaging’s platform is MaxQ AI’s intracranial hemorrhage detection algorithm.

Intracranial Bleed Detection Technology

Tel Aviv, Israel – November 22, 2016 – MedyMatch Technology Ltd., (“MedyMatch”) the deep learning and artificial intelligence company, announced today that after several years of extensive research and development, it has achieved a major milestone in the availability, for research, of an artificial intelligence-based technology that can help detect the presence of intracranial hemorrhage or brain bleed which can occur in cases of brain trauma and stroke. Subtle bleeds are difficult to detect and if misinterpreted or missed by a physician can lead to serious patient injury and even death.